Contrasting Second Sight Medical Products (EYES) and Uroplasty (UPI)

Second Sight Medical Products (NASDAQ: EYES) and Uroplasty (NASDAQ:UPI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Second Sight Medical Products and Uroplasty, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
Uroplasty 0 0 0 0 N/A

Second Sight Medical Products presently has a consensus target price of $5.00, suggesting a potential upside of 148.76%. Given Second Sight Medical Products’ higher probable upside, equities research analysts clearly believe Second Sight Medical Products is more favorable than Uroplasty.

Valuation & Earnings

This table compares Second Sight Medical Products and Uroplasty’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Second Sight Medical Products $3.98 million 28.69 -$33.17 million ($0.64) -3.14
Uroplasty N/A N/A N/A ($0.30) -4.07

Uroplasty has lower revenue, but higher earnings than Second Sight Medical Products. Uroplasty is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.8% of Second Sight Medical Products shares are owned by institutional investors. 34.7% of Second Sight Medical Products shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Second Sight Medical Products has a beta of 3.67, suggesting that its share price is 267% more volatile than the S&P 500. Comparatively, Uroplasty has a beta of -1.26, suggesting that its share price is 226% less volatile than the S&P 500.

Profitability

This table compares Second Sight Medical Products and Uroplasty’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -565.12% -184.87% -137.77%
Uroplasty -31.58% -87.33% -60.82%

Summary

Second Sight Medical Products beats Uroplasty on 6 of the 10 factors compared between the two stocks.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply